Simplify Logo

Full-Time

Principal Scientist

Translational Hematology

Posted on 4/3/2024

Verve Therapeutics

Verve Therapeutics

201-500 employees

Developing gene editing therapies for heart disease

Hardware
Biotechnology
Healthcare

Expert

Cambridge, MA, USA

Category
Lab & Research
Interdisciplinary Research
Life Sciences
Required Skills
Communications
Requirements
  • Ph.D. in biology or associated life science discipline with strong background/experience in hematology
  • At least 10 years of relevant experience
  • Strong hands-on experience with translational lab methodologies (ex. cell-based techniques, ex-vivo drug testing and models, PK/PD assays)
  • Ability to collaborate and influence at all levels across an organization
  • Exceptional written and verbal communication allowing oneself to communicate scientific data and information to others in a digestible format
  • Analytical mindset and good problem-solving ability
  • Demonstrated ability to critically evaluate and contribute to multiple scientific programs
  • Diligence and attention to detail
  • Good organizational skills
Responsibilities
  • Design and coordinate studies to understand the potential effects of gene editing products
  • Interpret and report data from investigative and translational studies to drive mechanistic understanding
  • Facilitate appropriate incorporation of translational medicine strategies for early and late phases of development
  • Implement and coordinate innovative biomarkers for defined endpoints based on the best available science and emerging multi-omic technologies
  • Utilize literature reviews, protocols, networking, and prior laboratory experience to advance the pre-clinical and clinical goals of the organization
  • Author research papers, abstracts, technical reports, and sections of regulatory documents
  • Present and communicate research findings to internal and external collaborators
  • Collaborate with internal and external stakeholders
  • Perform other duties within the nonclinical development department as assigned

Verve Therapeutics is developing single-course gene editing medicines to address cardiovascular disease, with a focus on precision genetic editing technologies to lower LDL cholesterol and triglyceride levels. Their lead program, VERVE-101, targets heterozygous familial hypercholesterolemia, a potentially fatal genetic heart disease.

Company Stage

IPO

Total Funding

$419.3M

Headquarters

Cambridge, Massachusetts

Founded

2018

Growth & Insights
Headcount

6 month growth

7%

1 year growth

5%

2 year growth

54%
INACTIVE